AVA-6000 is under clinical development by Avacta Life Sciences and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase I drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AVA-6000’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVA-6000 overview
AVA-6000 is under development for advanced or metastatic solid tumours which are known to be FAP positive including pancreatic, colorectal, breast, ovarian, bladder and non-small cell lung cancers, squamous cell carcinoma of the head and neck and soft-tissue sarcoma, salivary gland cancer, esophageal cancer, metastatic biliary tract cancer, undifferentiated pleomorphic sarcoma (UPS) and pancreatic ductal adenocarcinoma. The drug candidate is an affimer conjugated to pro-doxorubicin. It acts by targeting FAP. The drug candidate is developed based on the Tufts technology and pre|CISION technology . It is administered through intravenous route.
Avacta Life Sciences overview
Avacta Life Sciences operates within the pharmaceuticals and healthcare industry, specifically focusing on research and developing novel therapeutics and diagnostics for the treatment of cancer diseases. The company is headquartered in Wetherby, England, the UK.
For a complete picture of AVA-6000’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
